Author:
Gan Junqing,Liu Meiyue,Liu Fei,Wen Junxiu,Fu Wenjuan,Jia Jinghao
Abstract
Abstract
Background
Although lung and breast cancers are common malignancies, the occurrence of primary synchronous neoplasms involving these organs has been rarely reported in literature.
Case presentation
A 75-year-old female patient presented at a local hospital with a ten-day history of dizziness and slurred speech. A CT contrast-enhanced scan revealed a 4.2 cm mass in the lower lobe of the right lung and a 3.8 cm space-occupying lesion in the right breast. Subsequent breast ultrasound identified a hypoechoic lesion measuring5.41 × 4.75 × 3.06 cm in the right breast, and an ultrasound-guided biopsy confirmed the presence of infiltrating ductal carcinoma of the right breast. The immunohistochemistry analysis of the breast mass revealed positive staining for ER, PR, HER-2, AR and Ki67 in the tumor cells, while negative staining was observed for P63, Calponin, CK5/6 and CK14. MR imaging of the head detected abnormal signals in the right frontal lobe (3.6 cm×2.9 cm in size), left cerebellar hemisphere, and punctate enhancement in the left temporal lobe, indicating potential metastasis. Pathological examination of a lung biopsy specimen confirmed the presence of small cell lung cancer (SCLC). Furthermore, immunohistochemistry analysis of the lung lesions demonstrated positive staining for TTF-1, CK-Pan, Syn, CgA, CD56, P53 (90%) and Ki67 (70%), and negative staining for NapsinA and P40 in the tumor cells. The patient’s diagnosis of SCLC with stage cT2bN0M1c IVB and brain metastases (BM), as well as invasive ductal breast carcinoma (IDC), was confirmed based on the aforementioned results. Whereupon we proposed a treatment plan consisting of whole-brain radiation (40 Gy/20fractions), focal radiotherapy (60 Gy/20fractions), and adjuvant concurrent chemotherapy with oral etoposide (50 mg on days 1 to 20).
Conclusions
To the best of our knowledge, the present case is the first of its kind to describe the synchronous double cancer, consisting of primary SCLC and IDC.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Liu Z, Jin C, Zhang Y, Jiang Y, Wang J, Zheng L. Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature. World J Surg Oncol. 2023;21(1):158.
2. Nyqvist J, Parris TZ, Helou K, Sarenmalm EK, Einbeigi Z, Karlsson P, Nasic S, Kovács A. Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018. Breast Cancer Res Treat. 2020;184(1):221–8.
3. Zhai C, Cai Y, Lou F, Liu Z, Xie J, Zhou X, Wang Z, Fang Y, Pan H, Han W. Multiple primary malignant tumors - a clinical analysis of 15,321 patients with malignancies at a single center in China. J Cancer. 2018;9(16):2795–801.
4. Xia Q, Zhao LY, Yan YD, Liao Y, Di YS, Xiao XY. A multiple primary malignancy patient with FANCA gene mutation: a case report and literature review. Front Oncol. 2020;10:1199.
5. Shoji F, Yamashita N, Inoue Y, Kozuma Y, Toyokawa G, Hirai F, Ito K, Tagawa T, Okamoto T, Maehara Y. Surgical resection and outcome of synchronous and metachronous primary lung cancer in breast cancer patients. Anticancer Res. 2017;37(10):5871–6.